NCT06308913 2026-04-22
Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma
University of Wisconsin, Madison
Phase EARLY_PHASE1 Active not recruiting
Clinical Trials
7 trialsNCT04134325 2026-04-17
Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT03832569 2026-03-05
Study of Pembrolizumab Following Surgery in Patients With Microsatellite Instability High (MSI-H) Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT05358938 2026-02-06
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT02603887 2026-01-29
Pembrolizumab in Treating Patients With Intermediate or High-Risk Smoldering Multiple Myeloma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT05488366 2025-09-22
Immunotherapy Combined With Radiotherapy for Metastatic Sarcoma
University of California, Irvine
Phase EARLY_PHASE1 Active not recruiting
NCT02872025 2025-01-30
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
University of California, San Francisco
Phase EARLY_PHASE1 Active not recruiting